Eli Lilly & Co.'s rheumatoid arthritis drug and GlaxoSmithKline Plc's monoclonal antibody won the backing of World Health Organization experts for treating Covid-19 as new infections surge across the globe.
Feb 4, 2021
AZD1222 appears effective, reduces positive PCR tests
Early results from three trials assessing the safety and efficacy of the Oxford University/AstraZeneca Covid-19 vaccine, AZD1222, suggest that a single dose of the vaccine is 76% effective in preventing SARS-CoV-2 infection and the shot may also reduce onward transmission of the virus, researchers reported.
Oxford University explained that the study results which were published in
The Lancet showed “a single standard dose (SD) of the vaccine reduced PCR positivity by 67%, and that, after the second dose, the SD/SD schedule reduced PCR positivity by 49.5% overall,” according to Andrew J. Pollard, MRCP, FHEA, FIDSA, FRCPCH, and colleagues from the Oxford Vaccine Group. “These data indicate that [AZD1222], used in the authorized schedules, may have a substantial impact on transmission by reducing the number of infected individuals in the population.” The study authors also reported that participants age